Unveiling a Rare and Aggressive Bladder Tumor: A Case Report of Plasmacytoid Urothelial Carcinoma

In 1991, Sahin et al. reported the first documented case of plasmacytoid urothelial carcinoma (PUC). A rare and highly aggressive subtype that was recently incorporated into the WHO classification of urothelial carcinomas, representing 1-3% of cases of bladder cancers. The tumor cells are characterized by eccentrically placed nuclei with abundant eosinophilic cytoplasm and demonstrate positive immunostaining for CD138, and this variant is generally linked to an unfavorable prognosis. In this article, we present the case of a 61-year-old male diagnosed with PUC managed with concurrent chemoradiotherapy.

Authors

Publication Details

Journal
Cureus
Published
2026-03-15
DOI
https://doi.org/10.7759/cureus.105275
Primary Topic
Bladder and Urothelial Cancer Treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Unveiling a Rare and Aggressive Bladder Tumor: A Case Report of Plasmacytoid Urothelial Carcinoma

Soufiane Berhili, Loubna Mezouar, Mohammed Amine Guerrouaz, Ahmed BenSghier et al.
Cureus
Bladder and Urothelial Cancer Treatments
article

Unveiling a Rare and Aggressive Bladder Tumor: A Case Report of Plasmacytoid Urothelial Carcinoma

Soufiane Berhili, Loubna Mezouar, Mohammed Amine Guerrouaz, Ahmed BenSghier, Mohamed Moukhlissi, Fatima Zahra Bouayed, Hanane Sebbar
article en

Abstract

In 1991, Sahin et al. reported the first documented case of plasmacytoid urothelial carcinoma (PUC). A rare and highly aggressive subtype that was recently incorporated into the WHO classification of urothelial carcinomas, representing 1-3% of cases of bladder cancers. The tumor cells are characterized by eccentrically placed nuclei with abundant eosinophilic cytoplasm and demonstrate positive immunostaining for CD138, and this variant is generally linked to an unfavorable prognosis. In this article, we present the case of a 61-year-old male diagnosed with PUC managed with concurrent chemoradiotherapy.

Cureus
Good health and well-being
Openalex Percentile: Top 22%
Bladder and Urothelial Cancer Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.